期刊文献+

应用定量构效关系预测技术控制药物毒性杂质的探讨与展望 被引量:3

Update on Drug Impurity Control:(Q)SAR Prediction for Toxicity
下载PDF
导出
摘要 目的全面追踪和探讨目前国际上应用定量构效关系预测药物毒性杂质的前沿技术和发展方向。方法全文检索和查阅近年来有关定量构效关系预测毒性技术的文献和专利,以及对相关软件在使用过程中的总结体会。结果与结论运用已知机理的经验导出法、化合物结构导出法、类似物导出法和无经验参照的统计学方法,可以对未知化合物进行毒性预测。该前沿技术的应用可以大大提高质控水平和效率,提升药品监管能力,并节省实验资源耗费。 Objective To review and discuss the latest development of(Q)SAR prediction for toxicity in drug quality control.Methods The development of(Q)SAR prediction for toxicity control was summarized and investigated by means of literature and patent searching.Results and Conclusion(Q)SAR prediction for toxicity control can be achieved by knowledge-based approaches,structural based methods,analogue-based approaches and unsupervised statistical analyses.The application of these state-of-the-art techniques would improve the level of drug quality control,benefit the drug control authorities,and save the cost on animal tests.
出处 《中国药事》 CAS 2011年第7期710-712,共3页 Chinese Pharmaceutical Affairs
关键词 定量构效关系 毒性杂质 质量控制 (Q)SAR toxic impurity quality control
  • 相关文献

参考文献8

  • 1Guideline on the Limits of Genotoxic Impurities [S] . EMEA [2006-06-28] .
  • 2Guidance for Industry Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches [S] .FDA [2008-12-03] .
  • 3Benigni R, Netzeva T 1, Benfenati E, et al. The expanding role of predictive toxicology: an update on the (Q) SAR models of mutagens and carcinogens [J]. Environ Sci Health C, 2007, 25:53-97.
  • 4Dearman R J, Kimber I. Factors influencing the induction phase of skin sensitization[J].Am J Contact Dermat, 2003, 14: 188-194.
  • 5Benigni R. Structure-activity relationship studies of chemical mutagens and cacinogens: mechanistic investigations and pre- diction approaches [J]. Chem Rev, 2005, 105: 1767-1800.
  • 6Tong W, Xie Q, Hong H, et al. Assessment of prediction confidence and domain extrapolation of two structure-activity relationship models for predicting estrogen receptor binding activity [J].Toxicogenomics, 2004, 112: 1249-1254.
  • 7Verhaar H J M, Solbe J, Speksnijder J, et al. Classifying en- vironmental pollutants: Part3. External validation of the classification system [J].Chemosphere, 2000, 40: 875- 883.
  • 8Helma C, Kazius J. Artificial intelligence and data mining for toxicity prediction[EB/OL] . [2005-12-13], http: // www. in-silico, de/articles/helma _ kazius _ eeadd, pdf.

同被引文献65

  • 1张劲强,梁岩,董元华,黄铭洪.差向异构对四环素类药物的发光菌毒性研究[J].毒理学杂志,2006,20(5):279-281. 被引量:17
  • 2顾立素,张斗胜,胡昌勤.探讨静脉输液渗透压质量控制中存在的问题[J].中国药品标准,2007,8(1):19-21. 被引量:14
  • 3王佳佳,徐超,屠云杰,傅正伟,刘维屏.斑马鱼及其胚胎在毒理学中的实验研究与应用进展[J].生态毒理学报,2007,2(2):123-135. 被引量:61
  • 4SNODIN D J, MCCROSSEN SD. Guidelines and pharmacopoe- ial standards for pharmaceutical impurities:Overview and critical assessment[ J ]. Regul Toxicol Pharmacol, 2012,63 ( 2 ) : 298 - 312.
  • 5SUTTER A, AMBERG A, BOYER S, et al. Use of in sillco sys- tems and expert knowledge for structure-based assessment of po- tentially mutagenic impurities [ J ]. Regul Toxicol Pharmacol, 2013, 67(1) :39 -52.
  • 6ICH. M7 : Assessment and Control. of DNA Reactive (. Mutagemc) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk[ S]. 2010.
  • 7ICH.S2 ( R1 ) : Genotoxieity Testing and Data Interpretation for Pharmaceuticals for Human Use[ S]. 2012.
  • 8EMEA. Guideline on the Limits of Genotoxic Impurities[ S ]. 2006.
  • 9EMEA. Questions and Answers on the Guidance on the Limits of Geuotoxic impurities[ S ]. 2010.
  • 10FDA. Guidance for Industry, Genotoxic and Carcinogenic Impuri- ties in Drug Substances and Products:Recommended Approaches I sl. 2008.

引证文献3

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部